Jazz Pharmaceuticals plc — FY2023 Form 10-K
Reporting period: Year ended December 31, 2023; filed February 28, 2024. This is an annual report, not a standalone fourth-quarter filing, and the supplied text does not provide a clear Q4-only set of financial results.
Business context
Jazz is a global biopharmaceutical company focused on neuroscience and oncology. Its principal commercial products include Xywav, Xyrem and Epidiolex/Epidyolex, alongside Rylaze, Zepzelca, Defitelio and Vyxeos. Management’s Vision 2025 priorities are commercial execution, pipeline productivity and operational excellence.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $3,834.2 million | $3,659.4 million | +5% |
| Net product sales | $3,736.9 million | $3,641.4 million | +3% |
| Operating income (loss) | $578.6 million | $(65.5) million | Returned to operating profit |
| Net income (loss) | $414.8 million | $(224.1) million | Returned to net profit |
| Diluted earnings (loss) per share | $6.10 | $(3.58) | Improved |
| Operating cash flow | $1,092.0 million | $1,272.0 million | Down $180.0 million |
| Gross margin on net product sales, as reported | 88.3% | 85.2% | Up 3.1 percentage points |
Product sales highlights: Xywav sales rose 33% to $1,273.0 million; Xyrem fell 44% to $569.7 million; Epidiolex/Epidyolex rose 15% to $845.5 million; Rylaze rose 40% to $394.2 million; Zepzelca rose 7% to $289.5 million; Defitelio/defibrotide fell 5% to $184.0 million; and Vyxeos rose 15% to $147.5 million. High-sodium oxybate authorized-generic royalties contributed $75.9 million in 2023.
Expenses and unusual items: R&D expense increased 44% to $849.7 million, primarily reflecting clinical programs including zanidatamab. SG&A decreased 5% to $1,343.1 million, notwithstanding an approximately $61.7 million facility-asset impairment. FY2023 also included $19.0 million of acquired in-process R&D expense. FY2022 included $444.1 million of acquired in-process R&D expense and a $133.6 million impairment charge for the discontinued nabiximols program, materially affecting the year-over-year operating comparison.
Liquidity and debt at year-end: Cash and cash equivalents were $1,506.3 million, with $120.0 million of investments; total cash, cash equivalents and investments were $1.626 billion. Current assets were $3.435 billion and current liabilities were $1.537 billion. Debt carrying value was $5.713 billion; scheduled principal maturities totaled approximately $5.798 billion, including $575 million of exchangeable notes due August 2024. The $500 million revolving credit facility was undrawn. The company repurchased 2.1 million shares for $269.8 million during 2023; $161.4 million remained authorized at year-end.
Material changes versus FY2022
- Revenue grew, but neuroscience revenue declined 2% as Xywav growth and higher Epidiolex sales did not offset the Xyrem decline and Sunosi divestiture; oncology revenue increased 16%.
- Xywav continued to gain patients, including in idiopathic hypersomnia, while Xyrem sales were pressured by patient transitions to Xywav and high-sodium oxybate competition. Management reported approximately 12,300 patients taking Xywav at year-end.
- Operating and net results moved from losses to profits, mainly against FY2022’s much higher acquired R&D and impairment charges. Operating cash flow decreased from $1.272 billion to $1.092 billion.
- Debt remained substantial. The $575 million 2024 notes became current at year-end. In January 2024, the company repriced its dollar term loan, reducing the applicable margin by 50 basis points.
- The company reported revenue diversification: 50% of FY2023 total revenue came from outside its Sleep products, Xywav and Xyrem, plus high-sodium oxybate AG royalties.
Outlook, commentary and principal risks
- 2024 outlook: Management expects net product sales to increase, led by Xywav, Epidiolex and Rylaze, partly offset by lower Xyrem sales. It expects royalty and contract revenue to increase significantly, primarily due to the higher fixed royalty rate under the Hikma AG agreement. Management also expects higher cost of product sales, SG&A and R&D; no numerical full-year guidance is provided in the supplied text.
- Competition and concentration: Oxybate remains a significant revenue driver. Lumryz launched in the U.S. in 2023; authorized generics already affect the market, and potential generic Xywav and Epidiolex competition remains relevant. Hikma elected to continue its AG sales arrangement for up to four years beginning January 2024, subject to termination provisions.
- Pipeline execution: Zanidatamab’s rolling BLA submission for second-line biliary tract cancer began in Q4 2023; Phase 3 work in gastroesophageal cancer continues. Zepzelca remains under accelerated approval pending confirmatory evidence. The JZP150 PTSD trial missed its primary endpoint, and the JZP441 program was paused while safety findings related to visual disturbances and cardiovascular effects are assessed.
- Legal and regulatory contingencies: The company is challenging FDA’s approval and orphan exclusivity for Lumryz. Xyrem antitrust litigation includes a scheduled October 2024 trial; separate patent disputes and generic-entry settlements could affect market timing. The company also disclosed a U.S. Attorney’s Office investigation, under which it is cooperating, concerning Xyrem, patents, labeling, FDA/USPTO communications and pricing. Outcomes and potential financial effects are uncertain.
- Other material risks: Approximately $5.8 billion of debt constrains flexibility and exposes the company to variable rates; a 1% rate movement was estimated to change 2024 interest expense by about $22.1 million on unhedged borrowings. The company also cites reimbursement and pricing pressure, single-source supply dependencies, product safety and REMS obligations, intellectual-property challenges, clinical-trial uncertainty, foreign-exchange exposure and cybersecurity threats.
- Financial reporting: KPMG issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. KPMG identified the Vyxeos intangible-asset recoverability assessment, particularly revenue forecasts, as a critical audit matter; no impairment was recorded for that asset in 2023.
Investor verification priorities
- Track Xywav patient growth and sales against Xyrem erosion, generic/AG competition and the 2024 Hikma royalty contribution.
- Review the 2024 maturity and settlement of the $575 million exchangeable notes, term-loan repricing effects, debt repayments and covenant headroom.
- Assess whether the expected growth in Epidiolex and Rylaze, and the zanidatamab development program, offset product declines and rising R&D investment.
- Monitor Zepzelca confirmatory-trial progress, JZP441’s safety review, and the outcomes or timing of the disclosed antitrust, FDA and patent proceedings.
- Verify gross-to-net deductions and rebate trends: total sales deductions were $1.019 billion, or 21.4% of gross product sales, in 2023; management expects rebates as a percentage of gross sales to increase in 2024.